This week in deals and financing, United Family Healthcare, a China hospital chain, will be acquired by New Frontier Corp from TPG and Fosun Pharma at an expected value of $1.44 billion. 
• Shenzhen Chipscreen Bio raised $148 million in a Shanghai STAR Board IPO at a $1.2 billion valuation, the first China pharma to list on the new exchange; 
• Hinova Pharma of Chengdu completed a $40 million Series B round for China-US Phase III trials of a prostate cancer treatment; 
• Huadong Medicine will pay $60 million for China/Asian rights to a portfolio of optical medical diagnostic devices from MediBeacon of the US; 
• TriArm Therapeutics of Shanghai completed a $20 million Series A to develop its CD19 CAR-T product with a two-day manufacturing process;
• Jiangsu Zecheng Biotech completed a $26 million C Round to support its in vitro automatic chemiluminescence-based diagnostic tests;
• Jiangsu Qyuns Therapeutic of Taizhou raised $20 million in a Series B to develop monoclonal antibody drugs for autoimmune diseases; 
• CGene Tech, a Suzhou BioBay company, announced a $14.5 million Series A+ financing to support a novel DPP-4 inhibitor for type 2 diabetes; 
• Zspeplib completed a $14 million Series A financing to build a peptide library using compression technology for drug discovery;
• Sihuan Pharma will form a JV with India's Strides to bring four Stride drugs to China;
• Xiamen Weiyang Pharma struck a deal to in-license China rights for a low-dose oral interferon alpha (IFNa) technology from Amarillo Biosciences of Texas;

Trials and Approvals

• CANbridge Pharma of Beijing filed an NDA in China for a rare disease treatment that targets Hunter Syndrome;
• I-Mab Biopharma, a Shanghai-San Diego biopharma, announced Tracon has begun a US Phase I trial of I-Mab's CD73 antibody in patients with solid tumors; 
• Xynomic Pharma, a US-China oncology company, has been approved to conduct two China pivotal trials of its lymphoma treatment.